DNA lipid complex gene delivery systems - Valentis

Drug Profile

DNA lipid complex gene delivery systems - Valentis

Latest Information Update: 21 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source; Valentis
  • Developer DSM; Valentis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Cystic fibrosis; Head and neck cancer; Ischaemic heart disorders; Osteoarthritis; Peripheral vascular disorders; Rheumatoid arthritis; Solid tumours; Transplant rejection

Most Recent Events

  • 19 Oct 2005 A preclinical study has been added to the Cancer pharmacodynamics section
  • 03 Apr 2001 Discontinued-II for Cystic fibrosis in USA (Inhalation)
  • 22 Jun 1999 The GeneMedicine/Megabios merged company is now called Valentis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top